FPWR Blog

Based on the review of data from more than 50% of patients enrolled, the Data Safety Monitoring Board has recommended continuing a  phase III clinical trial of DCCR for PWS. The trial, called DESTINY PWS, is a randomized, double-blind, placebo-controlled study of once daily oral administration of...
Source: FPWR Blog | Published: October 10 2019 - 09:00 AM
Drug development is a long and costly process that can take up to 15 years and cost up to one billion dollars! In this 7-minute video, Dr. Theresa Strong discusses the stages of PWS Drug Development. Don't have time for the full presentation? We've captured the key points in the notes below.
Source: FPWR Blog | Published: October 10 2019 - 09:25 PM
In 2015 FPWR co-funded a phase 2 study to investigate diazoxide choline controlled-release in patients with PWS. Results from the study were recently published in PLoS ONE and are summarized below.
Source: FPWR Blog | Published: October 10 2019 - 09:00 AM